

Selected Protocols for the Treatment of Pediatric Cancer and Blood Disorders

This listing changes frequently. For more information about the trials we have available please contact dfchcc_clinicaltrials@dfci.harvard.edu

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
BRAIN TUMORS			
Diffuse Intrinsic Pontine Glioma (DIPG)	Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Glioma	10-321/II	Mark W. Kieran, MD, PhD 617-632-4386
Ependymoma	A Phase II Multi-Institutional Trial of Focal Radiotherapy with Concomitant Carboplatin as a Radiosensitizer and the Prospective Analysis of Survivin, an Inhibitor of Apoptosis, as a Biomarker in Children with Newly Diagnosed Non-Metastatic Ependymoma and Minimal Residual Disease Post-Operatively	10-395/II	Susan Chi, MD 617-632-4386
Ependymoma (Recurrent)	Erlotinib vs Etoposide for Recurrent Ependymoma	10-093/II	Mark W. Kieran, MD, PhD 617-632-4386
High Grade Glioma	A Phase I Study of AdV-tk + Prodrug Therapy in Combination with Radiation Therapy for newly diagnosed malignant glioma	07-098/I	Mark W. Kieran, MD, PhD 617-632-4386
High Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG)	Cetuximab, Irinotecan and XRT for Newly Diagnosed HGG and Diffuse Intrinsic Pontine Glioma	09-123/II	Mark W. Kieran, MD, PhD 617-632-4386
Low Grade Glioma and Neurofibromatosis type 1	A Phase II Study of RAD001 (Everolimus) for Children with Neurofibromatosis type I and Chemotherapy-Refractory Progressive or Recurrent Low-Grade Gliomas (DOD)	09-452/II	Mark W. Kieran, MD, PhD 617-632-4386
Recurrent Brain Tumors	A phase I study of LDE225 in Pediatric patients with recurrent or refractory Medulloblastoma, or other tumors potentially dependent on Hedgehog signaling pathway	10-358/I	Mark W. Kieran, MD, PhD 617-632-4386
BENIGN HEMATOLOGY			
Sickle Cell Disease	Stroke With Transfusions Changing to Hydroxyurea (SWITCH): A Phase III randomized clinical trial to compare standard therapy (erythrocyte transfusions with iron chelation) with alternative therapy (hydroxyurea with phlebotomy) for the prevention of secondary stroke and the management of iron overload in pediatric subjects with sickle cell anemia and previous stroke	06-11-0498	Matthew Heeney, MD 617-355-7700
Fanconi Anemia/ Dyskeratosis Congenita	Phase I/II Dose Escalation Trial of Danazol in Patients with Fanconi Anemia or Dyskeratosis Congenita	09-03-0131/I-II	Colin Sieff, MB BCH 617-919-4241

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
BENIGN HEMATOLOGY (continued)			
Hemophilia	Pediatric Phase IIIb Trial of rFVIII (N8) in Patients with Hemophilia A	P00001174/III	Kapil Saxena, MD 617-355-4977
Hemophilia	Bleeding in Surgical Interventions or Invasive Procedures in Hemophilia A or B Patients with Inhibitors to Factor FVIII or Factor IX	P00001088/III	Kapil Saxena, MD 617-355-4977
Idiopathic Thrombocytopenic Purpura	A Three-Part, Staggered Cohort, Open-Label and Double-Blind, Randomized, Placebo Controlled Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of Eltrombopag, a Thrombopoietin Receptor Agonist, in Previously Treated Pediatric Patients with Chronic Idiopathic Thrombocytopenic Purpura (ITP)	10-02-0056/III	Ellis Neufeld, MD, PhD 617-919-2139
Idiopathic Thrombocytopenic Purpura	Initial Treatment of Patients with Immune Thrombocytopenic Purpura	10-030	Ellis Neufeld, MD, PhD 617-919-2139
Iron Overload	A Phase 2, Open Label, Multi-Center Single-Dose Pharmacokinetics, and Multiple Dose Study of the Safety, Efficacy and Tolerability of FBS0701 in Pediatric Population with Transfusional Iron Overload	P00000983	Rachel Grace, MD 617-919-2144
Myelodysplastic Syndrome/ Bone Marrow Failure Disorders	Pediatric Myelodysplastic Syndrome and Bone Marrow Failure Disorder Patient Registry and Tissue Repository	10-02-0057	Inga Hofmann, MD 617-355-2463
Severe Combined Immuno- deficiency Syndrome (SCID)	Gene Transfer for SCID-X1 Using a Self-Activating (SIN) Gammaretroviral Vector	09-05-0254	Luigi Notarangelo MD 617-919-2276
Sickle Cell Disease	Safety of Adenosine 2A Agonist Lexiscan in Children and Adults with Sickle Cell Disease	09-308/I	Matthew Heeney, MD 617-355-7700
Sickle Cell Disease	Sickle Cell Study of Prasurigel	P00001064	Matthew Heeney, MD 617-355-7700
Sickle Cell Disease	TCD with Transfusions Changing to Hydroxyurea	P00001496/III	Matthew Heeney, MD 617-355-7700
Thalassemia	Health-Related Quality of Life in Patients Requiring Chronic Red Cell Transfusions: Validation Study (TranQOL)	X10-05-0249	Ellis Neufeld, MD, PhD 617-919-2139
Thalassemia	A 5-Year Observational Study (Registry) of Children Aged 2 to <6 Years at Enrollment with Transfusional Hemosiderosis Treated with Deferasirox	X07-10-0437/ IV	Ellis Neufeld, MD, PhD 617-919-2139
Thalassemia	Thalassemia Data and Blood Specimen Collection System	03-10-163	Ellis Neufeld, MD, PhD 617-919-2139
Thalassemia	Thalassemia Longitudinal Cohort (Accrual Complete Except for Patients Undergoing Transplant)	06-10-0466/ Observational	Ellis Neufeld, MD, PhD 617-919-2139

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
Vascular Anomalies	Phase II clinical trial assessing efficacy and safety of the mTOR Inhibitor Sirolimus in the treatment of complicated vascular anomalies	P00001573/II	Cameron Trenor, MD (617) 919-3242
Wiskott-Aldrich Syndrome	Pilot and feasibility study of hematopoietic stem cell gene transfer for the Wiskott-Aldrich Syndrome	P00000148	Sung-Yun Pai, MD 617-919-2508
DEVELOPMENTAL THERAPEUTICS			
Solid Tumor (incl., Lymphoma) relapsed/refractory	A Phase I Study of Ipilimumab (Anti-CTLA-4) in Children, Adolescents, and Young Adults with Treatment Refractory Cancer	11-062/II	Carlos Rodriguez-Galindo, MD 617-632-4580
Solid Tumor, relapsed/refractory	A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors	10-010/I-II	Suzanne Shusterman, MD 617-632-4901
Solid Tumor, relapsed/refractory	Individualized Cancer Therapy (iCat) Recommendation for Patients with Recurrent, Refractory, or High Risk Solid Tumors	11-406	Katherine Janeway, MD 617-632-4994
Solid Tumor, relapsed/refractory	Phase I Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients with Relapsed or Refractory Solid Tumors	11-420/I	Carlos Rodriguez-Galindo, MD 617-632-4580
EMBRYONAL TUMORS			
Neuroblastoma (newly diagnosed)	A Comparative Pharmacokinetic and Safety Study of Chimeric Monoclonal Antibody ch 14.18 with Granulocyte-Macrophage-Colony-Stimulating-Factor (GM-CSF), Interleukin (IL-2) and Isotretinoin in high-Risk Neuroblastoma Patients Following Myeloblative Therapy	12-141	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	Phase I Study of Fenretinide (4-HPR, NSC 374551) Lym-X-sorb™(LXS) Oral Powder in Patients with Recurrent or Resistant Neuroblastoma (NANT 04-04)	05-302/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	An Open Label, Expanded Access Protocol Using 131I-Metaiodobenzylguanidine (131 I-MIBG) Therapy in Patients with Refractory Neuroblastoma	08-111/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	A Phase I Study of Bevacizumab with Bolus and Metronomic Cyclophosphamide and Zoledronic Acid in Children with Recurrent or Refractory Neuroblastoma (NANT 07-02)	09-078/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	Modulation of Intensive Melphalan (L-PAM) by Buthionine Sulf-oximine (BSO) with Autologous Stem Cell Support for Resistant/ Recurrent High-Risk Neuroblastoma (NANT99-02)	09-225/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	Vorinostat +131 I-MIBG for Relapsed Neuroblastoma (NANT N2007-03)	10-051/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	Phase I Study Of Vorinostat In Combination With 13-Cis-Retinoic Acid In Patients With Refractory/Recurrent Neuroblastoma (NANT 2008-02)	10-408/I	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, relapsed/refractory	A Phase I Trial Combining Decitabine and Vaccine Therapy for Patients with Neuroblastoma	11-130/I	Rani George, MD 617-632-5281

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
HEMATOLOGIC MALIGNANCY			
Langerhans Cell Histiocytosis (relapsed/refractory)	Phase II Study of Clofarabine in Patients with Recurrent or Refractory Langerhans Cell Histiocytosis	12-050	Carlos Rodriguez-Galindo, MD 617-632-4580
Leukemia (ALL/AML) Relapsed/refractory	AC 220 for Children with relapsed ALL or AML	12-076	Lewis Silverman, MD 617-632-6191
Hemophagocytic lymphohistiocytosis (HLH)	An open label study of Hybrid ImmunoTherapy (ATG/Dexamethasone/Etoposide) for Hemophagocytic Lymphohistiocytosis: HIT-HLH	11-243/II	Barbara Degar, MD 617-632-5186
Hodgkins Lymphoma (high risk)	Reduced Duration Stanford v Chemotherapy with Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma (HOD08)	09-273/II	Amy Billett, MD 617-632-5640
Leukemia (ALL) newly diagnosed	Randomized Study of Intravenous Calaspargase Pegol (SC-PEG asparaginase) and Intravenous Oncaspar in Children and Adolescents with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma.	11-001/III	Lewis Silverman, MD 617-632-6191
Leukemia (Infant ALL), newly diagnosed	Interfant-06 – International Collaborative Treatment Protocol for Infants under One Year with Acute Lymphoblastic Leukemia or Biphenotypic Leukemia	06-172/III	Lewis Silverman, MD 617-632-6191
Leukemia (ALL), relapsed/refractory	A Feasibility trial of Everolimus (RAD001), an mTOR inhibitor, given in combination with multiagent re-induction chemotherapy in pediatric patients with relapsed acute lymphoblastic Leukemia (ALL)	11-237/I	Lewis Silverman, MD 617-632-6191
Leukemia (ALL), relapsed/refractory	Clofarabine with Cytarabine for MRD Positive Leukemia	11-338/II	Lewis Silverman, MD 617-632-6191
Leukemia (ALL/AML), relapsed/refractory	A Phase I, Open-Label, Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Twice Daily Oral Midostaurin and to Evaluate the Preliminary Clinical and Pharmacodynamic Response in Pediatric Patients with Relapsed or Refractory Leukemia	09-238/I	Lewis Silverman, MD 617-632-6191
Leukemia (ALL), relapsed/refractory	A Phase I Trial of CAT-8015 (Toxin-conjugated anti-CD22) for Relapsed, Refractory B-precursor ALL	09-340/I	Lewis Silverman, MD 617-632-6191
Leukemia (ALL), relapsed/refractory	A Phase I Trial of Nelarabine, Cyclophosphamide, Etoposide in Relapsed, Refractory T-Cell ALL	10-052/I	Lewis Silverman, MD 617-632-6191
Leukemia (AML)	AML08: A Phase III Radomized Trial of Clofarabine Plus Cytarabine versus Conventional Induction Therapy and a Phase II Study of Natural Killer Cell Transplantation in Patients with Newly Diagnosed Acute Myeloid Leukemia (St. Jude).	09-337/III	Barbara Degar, MD 617-632-5186
Leukemia (CML and Ph+ leukemias)	A Phase II Study of Dasatinib Therapy in Children and Adolescents with Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia or with Ph+ Leukemias Resistant or Intolerant to Imatinib	11-084/II	Barbara Degar, MD 617-632-5186

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
RARE AND ADULT CANCERS			
Gastrointestinal Stromal Tumor	A Phase I/II Study of Sunitinib in Young Patients with Advanced Gastrointestinal Stromal Tumor	12-106	Katherine Janeway, MD 617-632-4994
Melanoma	An open-label, multicenter, single-arm, Phase I dose-escalation with efficacy tail extension study of RO5185426 in pediatric patients with surgically incurable and unresectable Stage IIIC or Stage IV melanoma harboring BRAFV600 mutations	11-388/I	Carlos Rodriguez-Galindo, MD 617-632-4580
SARCOMA			
Osteosarcoma, relapsed/refractory	A Randomized, Double-Blinded, Placebo-Controlled, Multi-Institutional, Phase II.5 Study of AZD0530, a Selective SRC Kinase Inhibitor, in Patients with Recurrent Osteosarcoma Localized to the Lung	09-473/II-III	Katherine Janeway, MD 617-632-4994
STEM CELL TRANSPLANTATION			
Stem Cell Transplantation (Dyskeratosis Congenita)	Non-TBI and alkylator-free conditioning for allogeneic bone marrow transplantation for bone marrow failure due to dyskeratosis congenita/telomere disease	P00003466	Suneet Agrawal, MD 617-919-4610
Stem Cell Transplantation (Severe Aplastic Anemia)	Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation From HLA-Compatible Unrelated Donors in Severe Aplastic Anemia (CTN 0301)	06-158/I-II	Leslie Lehmann, MD 617-632-4882
Stem Cell Transplantation (Fanconi Anemia)	A Multicenter Phase II Trial of Hematopoietic Stem Cell Transplantation for the Treatment of Patients with Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cyto-reduction with Busulfan, Cyclophosphamide and Fludarabine	08-377/II	David A. Williams, MD 617-919-2697
Stem Cell Transplantation (Cord Blood Unit access)	A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients with Hematologic Malignancies and Other Indications	11-297	Leslie Lehmann, MD 617-632-4882
Stem Cell Transplantation (Graft-Versus-Host Disease)	An Open Label Phase II Randomized trial of Topical Dexamethasone and Tacrolimus for the Treatment of Oral Chronic Graft-Versus-Host Disease	08-027/II	Nathaniel S. Treister, DMD 617-632-2806
Stem Cell Transplantation (Sickle Cell Disease)	Unrelated Donor Hematopoietic Stem Cell Transplantation for Children with Severe Sickle Cell Disease Using a Reduced Intensity Conditioning Regimen	09-141/II	Leslie Lehmann, MD 617-632-4882
Stem Cell Transplantation (Severe Thalassemia)	Unrelated Donor Hematopoietic Stem Cell Transplantation for Children with Severe Thalassemia Using Reduced Intensity Conditioning Regimen (The URTM Trial)	09-458/II	Leslie Lehmann, MD 617-632-4882
Stem Cell Transplantation (Severe Hepatic Venous-Occlusive Disease)	Defibrotide for Hematopoietic Stem Cell Transplant Patients with Severe Hepatic Venous-Occlusive Disease (VOD): A Treatment IND Study (UnderCFR312.34)	07-320/III	Leslie Lehmann, MD 617-632-4882
Stem Cell Transplantation (SCID)	Gene Transfer for SCID-X1 using a self-inactivating (SIN) gammaretroviral vector	09-05-0254	Luigi Notarangelo, MD 617-919-2276
Wiskott-Aldrich Syndrome	Pilot and feasibility study of hematopoietic stem cell gene transfer for the Wiskott-Aldrich Syndrome	P00000148	Sung-Yun Pai, MD 617-919-2508

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
OTHER			
Solid Tumor (relapsed/refractory)	A Phase I/II Clinical Study of Vorinostat in Combination with Etoposide in Pediatric Patients <21 Years at Diagnosis with Refractory Solid Tumors	12-003	Mark W. Kieran, MD, PhD 617-632-4368
Solid Tumor (Lung metastases)	Cardiac-Sparing Whole-Lung IMRT in Children and Young Adults with Lung Metastases: a Feasibility Study	10-463	Karen Marcus, MD 617-525-7386
Neurofibromatosis, plexiform neurofibromas	A Phase II Trial of Peginterferon alfa-2b (Pegintron) for Neurofibromatosis Type 1 Related Unresectable, Symptomatic or Life-Threatening Plexiform Neurofibromas	08-330/II	Mark W. Kieran, MD, PhD 617-632-4368
Neurofibromatosis	A Randomized Placebo-Controlled Study of Lovastatin in Children with Neurofibromatosis Type I (for Children with Cognitive and Attention Problems)	09-05-0228	Nicole Ullrich, MD, PhD 617-355-2066

Children's Oncology Group (COG) trials open at Dana-Farber/Children's Hospital Cancer Center

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
BRAIN TUMOR			
Atypical Teratoid/Rhabdoid Tumors (AT/RT)	Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System with Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation (ACNS0333)	11-092/III	Susan Chi, MD 617-632-4386
Diffuse Intrinsic Pontine Glioma (DIPG)	A Phase I/II Study of suberoylanilide hydroxamic acid (SAHA, Vorinostat) and Local Irradiation followed by Maintenance SAHA in Children with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas (DIPG) (ACNS0927)	11-032/I	Susan Chi, MD 617-632-4386
Ependymoma	Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 years (ACNS0831)	10-239/III	Susan Chi, MD 617-632-4386
Medulloblastoma	A Phase III Study Investigating the Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients (COG ACNS0332)	07-125/III	Susan Chi, MD 617-632-4386
Medulloblastoma (infants/toddlers)	Randomized Phase III Study for Patients with High Risk PNET/Medulloblastoma under the Age of 36 Months (COG ACNS0334)	07-308/III	Susan Chi, MD 617-632-4386
Medulloblastoma (Recurrent/Refractory)	Temozolomide with Irinotecan versus Temozolomide, Irinotecan plus Bevacizumab for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, A COG Randomized Phase II Screening Trial (ACNS0821)	11-150/II	Susan Chi, M.D. 617-632-4386
High Grade Glioma	A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children with Newly Diagnosed High-Grade Gliomas (ACNS0822)	11-079/II-III	Susan Chi, MD 617-632-4386

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
DEVELOPMENTAL THERAPEUTICS			
Solid Tumor (relapsed/refractory)	Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (IND# 69896) in Children and Young Adults with Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma (ADVL1121)	12-046	Carlos Rodriguez-Galindo, MD 617-632-4580
Solid Tumor, relapsed/refractory	A Phase I Dose Escalation Study of Seneca Valley Virus (SVV-001), a Replication-Competent Picornavirus, in Relapsed/Refractory Pediatric Patients with Neuroblastoma, Rhabdomyosarcoma, Ewing Family of Tumors, and Rare Tumors with Neuroendocrine (ADVL0911)	10-243/I	Suzanne Shusterman, MD 617-632-4901
Solid Tumor, relapsed/refractory	A Phase 1 Study of Temozolimus in Combination with Irinotecan and Temozolomide in Children, Adolescents, and Young Adults with Relapsed or Refractory Solid Tumors (ADVL0918)	10-248/I	Suzanne Shusterman, MD 617-632-4901
Solid Tumor, (incl., Leukemia) relapsed/refractory	A Phase 1 Study of MK-2206, an AKT inhibitor, in Pediatric Patients with Recurrent or Refractory Solid Tumors or Leukemia (ADVL1013)	11-058/I	Suzanne Shusterman, MD 617-632-4901
Solid Tumor, (incl., Leukemia) relapsed/refractory	A Phase II Study of MLN8237 (IND# 102984), a Selective Aurora A Kinase Inhibitor in Children with Recurrent/Refractory Solid Tumors and Leukemias (ADVL0921)	11-102/II	Suzanne Shusterman, MD 617-632-4901
Solid Tumor (incl, Lymphoma), relapsed/refractory	A Phase 1 Study of Imetelstat, a Telomerase Inhibitor, in Children with Refractory or Recurrent Solid Tumors and Lymphoma (ADVL1112)	11-183/I	Suzanne Shusterman, MD 617-632-4901
Solid Tumor (incl., Lymphoma), relapsed/refractory	A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and C-Met, in Children with Relapsed/Refractory Solid Tumors and Anaplastic Large Cell Lymphoma (COG ADVL0912)	09-347/I-II	Suzanne Shusterman, MD 617-632-4901
Solid Tumor, relapsed/recurrent	A Phase I Study of Irinotecan, Temozolomide and Temozolimus in Children with Refractory or Recurrent Solid Tumors (ADVL0918)	10-248/I	Suzanne Shusterman, MD 617-632-4901
Solid Tumor (Leukemia), relapsed/refractory	Phase 1 Study of JAK Inhibition (INCB018424) in Children with Relapsed or Refractory Solid Tumors, Leukemias, and Myeloproliferative Neoplasms (ADVL1011)	10-350/I	Allison O'Neill, MD 617-632-4202
EMBRYONAL TUMORS			
Hepatoblastoma	Treatment of Children with All Stages of Hepatoblastoma (COG identifier (AHEP 0731)	09-379/III	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, OMS	Use of Intravenous Gammaglobulin Therapy for Patients with Neuroblastoma Associated Opsoclonus-Myoclonus-Ataxia Syndrome Treated with Chemotherapy and Prednisone (ANBL00P3)	06-184/III	Suzanne Shusterman, MD 617-632-4901
Neuroblastoma, high risk	Phase III Randomized Trial of Single versus Tandem Myeloblastic as Consolidation Therapy for High-Risk Neuroblastoma (ANBL0532)	07-403/III	Suzanne Shusterman, MD 617-632-4901

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
EMBRYONAL TUMORS (continued)			
Neuroblastoma, relapsed/refractory	Feasibility/Phase II Study of hu14.18-IL2 immunocytokine + GM-CSF and Isotretinoin in Patients with Relapsed or Refractory Neuroblastoma (ANBL1021)	11-393/II	Elizabeth Mullen, MD 617-632-5186
Renal Tumors, high risk	Treatment of High Risk Renal Tumors (AREW0321)	06-263/III	Elizabeth Mullen, MD 617-632-5186
Wilms Tumor, low risk	Treatment for Very Low and Standard Risk Favorable Histology Wilms Tumor (AREW0532)	07-008/III	Elizabeth Mullen, MD 617-632-5186
Wilms Tumor, high risk	Treatment of Newly Diagnosed Higher Risk Favorable Histology Wilms Tumors (AREW0533)	07-095/III	Elizabeth Mullen, MD 617-632-5186
Wilms Tumor	Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor (AREW0534)	11-476/III	Elizabeth Mullen, MD 617-632-5186
HEMATOLOGIC MALIGNANCIES			
Leukemia (newly diagnosed)	A Phase 2 Multi-Center, Historically-Controlled Study of Dasatinib Added to Standard Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (AALL1122)	12-056	Lewis Silverman, MD 617-632-6191
Leukemia (APL), relapsed/refractory	Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) using Arsenic Trioxide (Trisenox, IND#103,331) during Consolidation (AAML0631)	10-112/III	Barbara Degar, MD 617-632-5186
RARE AND ADULT CANCERS			
Adrenocortical Tumors	Treatment of Adrenocortical Tumors with Surgery plus Lymph Node Dissection and Multiagent Chemotherapy (ARAR0332)	07-180/III	Carlos Rodriguez-Galindo, MD 617-632-4580
SARCOMA			
Ewing Sarcoma, non-metastatic	A Phase III Randomized Trial of Adding Vincristine-topotecan-cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-metastatic Ewing Sarcoma: A Groupwide Phase III Study (AEWS1031)	10-427/III	Katherine Janeway, MD 617-632-4994
Rhabdomyosarcoma, intermediate risk	Randomized Study of Vincristine, Dactinomycin and Cyclophosphamide (VAC) versus VAC Alternating with Vincristine and Irinotecan (VI) for Patients with Intermediate-Risk RMS (RMS) (ARST0531)	07-030/III	Carlos Rodriguez-Galindo, MD 617-632-4580
Rhabdomyosarcoma, high risk	A Pilot Study to Evaluate Novel Agents (Temozolomide and Cixutumumab [IMC-A12, Anti-IGF-IR Monoclonal Antibody, IND# 100947, NSC#742460]) in Combination with Intensive Multi-Agent Interval Compressed Therapy for Patients with High-Risk RMS (ARST08P1)	10-124/ Pilot	Carlos Rodriguez-Galindo, MD 617-632-4580
Rhabdomyosarcoma,, relapsed/refractory	A Randomized Phase II Trial of Bevacizumab (IND# 7921, Avastin) and Temozolomide (IND# 61010, Temisol) in Combination with Intravenous Vinorelbine and Cyclophosphamide in Patients with Recurrent/Refractory Rhabdomyosarcoma (COG ARST0921)	10-413/II	Carlos Rodriguez-Galindo, MD 617-632-4580

Treatment Area	Study Name	ID Number/ Phase	Site Investigator
STEM CELL TRANSPLANTATION			
Stem Cell Transplantation (Mucositis)	A Randomized Double Blinded Trial of Topical Caphosol to Prevent Oral Mucositis in Children Undergoing Hematopoietic Stem Cell Transplantation (ACCL1031)	11-301	Christine Duncan, MD 617-632-4882
Stem Cell Transplantation (Other)	A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT) (ACCL0934)	11-384	Christine Duncan, MD 617-632-4882

Dana-Farber/Children's Hospital Cancer Center represents the integrated pediatric oncology program at Dana-Farber Cancer Institute and Children's Hospital Boston. The more than 60-year-old program offers comprehensive care to children, adolescents, young adults, and survivors of all types of childhood cancers and related blood diseases.